Background: In a recent trial, cyclosporine A (CsA) failed to reduce infarct size in acute stroke patients treated with intravenous thrombolysis. White matter (WM) and gray matter (GM) may have distinct vulnerability to ischemia and response to therapy. Using final infarct size and lesion growth as endpoints, our objectives were to (1) investigate any tissue-specific effect of CsA and (2) compare WM and GM response to thrombolysis.
Background: In a recent trial, cyclosporine A (CsA) failed to reduce infarct size in acute stroke patients treated with intravenous thrombolysis. White matter (WM) and gray matter (GM) may have distinct vulnerability to ischemia and response to therapy. Using final infarct size and lesion growth as endpoints, our objectives were to (1) investigate any tissue-specific effect of CsA and (2) compare WM and GM response to thrombolysis.
Materials and methods:
We analyzed 84 patients from the randomized and placebocontrolled CsA-Stroke trial, who underwent MRI both on admission and at 1 month. Lesion growth was defined voxel-wise as infarcted tissue at 1 month with no visible lesion on baseline diffusion-weighted imaging. After automatic segmentation of GM/WM, final infarct size and lesion growth were compared within the GM and WM.
results: Occlusion level was distal (>M1) in 51% of cases. No significant difference in GM/WM proportions was observed within final infarcts between treatment groups (P = 0.21). Infarct size within the GM or WM was similar between the CsA and control groups [GM: 9.2 (2.4; 22.8) with CsA vs 8.9 (3.7; 28.4) mL with placebo, P = 0.74; WM: 9.9 (4.7; 25.4) with CsA vs 14.1 (5.6; 34.1) mL with placebo, P = 0.26]. There was no significant effect of CsA on lesion growth in either the GM or WM. Pooling all patients, a trend for increased relative lesion growth in WM compared to GM was observed [49.0% (14.7; 185.7) vs 43.1% (15.4; 117.1), respectively; P = 0.12].
conclusion: No differential effect of CsA was observed between WM and GM. Pooling all patients, a trend toward greater lesion growth in WM was observed.
Keywords: ischemic stroke, thrombolysis, neuroprotection, recanalization, cyclosporin inTrODUcTiOn Reperfusion can induce additional injury following prolonged periods of ischemia. CsA may limit reperfusion injury by inhibiting several mechanistic pathways: mitochondrial permeability transition pore opening, oxidative stress, microglial activation, and apoptosis (1) . CsA has reduced FigUre 1 | co-registered masks of acute diffusion-weighted imaging (DWi) lesion, final infarct, and corresponding lesion growth (a) overlaid on acute DWi, which were then segmented by the gray matter and white matter probabilistic maps (B). infarct size after percutaneous coronary intervention in acute myocardial infarction (2) . However, in a recent phase 2 trial, CsA failed to significantly reduce infarct size in acute stroke patients treated with intravenous tissue plasminogen activator (tPA) (3).
The failure of neuroprotection trials may in part stem from insufficient distinction between white matter (WM) and gray matter (GM) (4) . Indeed, few studies compared the vulnerability of WM and GM during ischemia, or their respective response to therapy (5-7). The effects of CsA may differ between these two compartments, which exhibit distinct cellular structure, metabolic, and hemodynamic requirements.
In this study involving patients treated with intravenous thrombolysis (no patient underwent mechanical thrombectomy), our objectives were to compare the final infarct size and lesion growth within WM and GM in (1) CsA vs placebo-treated patients, so as to assess any tissue-specific effect of CsA, and (2) a pooled analysis of all patients, to compare WM and GM response to ischemia and thrombolysis.
PaTienTs anD MeThODs

Patients
Cyclosporine A-stroke was a multicenter, randomized, singleblinded phase-II trial that enrolled patients aged 18-85 years presenting with an anterior-circulation stroke, a National Institutes of Health Stroke Scale score between 6 and 18, and who were treated by intravenous tPA within 4.5 h of symptoms onset. Patients received either a single intravenous bolus of CsA (2.0 mg/kg, Sandimmune, Novartis) or placebo. The primary endpoint was infarct size mapped on MRI at 1 month (3). For the present study, only patients with complete and assessable MRI at baseline and 1 month were included.
Mri Protocol
MRI was the first-line imaging method on admission and included diffusion-weighted imaging (DWI), T2*, fluid-attenuated inversion-recovery (FLAIR) and time-of-flight angiography. The same protocol was repeated at 1 month.
image analysis
Baseline DWI lesions and final infarcts on FLAIR were outlined as previously described (3). WM and GM were individually segmented from baseline T2* images using SPM8 (London, UK) (6). All baseline and 1-month images were co-registered within subjects. Lesion growth was defined as voxels included in the final FLAIR lesion, but not in the baseline DWI lesion. WM and GM masks were used to assess the volume and proportion of WM and GM within the final infarct and lesion growth (Figure 1) . Image analyses were performed using Matlab (MathWorks, USA).
statistical analyses
Results were described as proportions or median with interquartile range. Comparisons between treatment groups were 
WM vs gM in Pooled analyses
As CsA had overall no impact on imaging endpoints, we pooled all patients (CsA and placebo) to further explore any difference between GM and WM. Absolute infarct size was similar between GM and WM [9.2 mL (2.5; 26.1) vs 11.7 mL (5.5; 29.9), respectively; P = 
DiscUssiOn
In this study, we found no differential effect of CsA between WM and GM. Tissue-specific measurements showed no benefit of CsA in reducing lesion growth or infarct volume. CsA administration improved these endpoints in patients with proximal occlusion and subsequent recanalization, but to a similar extent in WM and GM. The potential benefit of CsA in this subgroup will require further evaluation, but our results do not suggest a tissue-specific response.
Whether GM and WM have a distinct vulnerability to ischemia remains controversial. Higher ischemic thresholds are found in GM compared to WM, but this may only reflect the inherent gap in metabolism and hemodynamics in these compartments (8) . Preclinical studies using different animal models yielded conflicting results (9, 10) . Positron-emission tomography and MRI-based clinical reports showed higher proportions of penumbral tissue within the WM compared to GM, suggesting a greater tolerance to ischemia in the former (5, 6) . However, in these untreated patients, similar proportions of at-risk WM and GM eventually infarcted. In our study, there was a trend toward increased lesion growth in WM in a pooled analysis of patients treated with intravenous tPA. This may suggest tissue-specific responses to ischemia-reperfusion, but needs confirmation in an adequately powered study.
Our report has some limitations. Reperfusion, penumbral tissue, and its evolution were not monitored, as perfusionweighted imaging was not systematically performed. The lack of high-resolution T1-weighted imaging may have impaired the precision of WM/GM segmentation. The main CsA-Stroke study was negative; the present report based on subgroup analyses may have an insufficient sample size and thus be underpowered to assess the differential effects of CsA in the WM and GM.
In conclusion, in our population of patients with distal or proximal occlusions, CsA had no significant effect on lesion growth and final infarct size in either the WM or GM. A trend toward greater lesion growth in WM was observed when pooling all patients.
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